



National Research Institution
for Public Health

RUSSIA

Khabriev R.U.¹, Bezmelnitsyna L.Y.¹, Meshkov D.O.¹, Markova E.Y.², Isaeva A.¹

¹National Research Institution for Public Health named N.A. Semachko, Moscow, Russia

²Intersectoral Research and Technology Complex Eye Microsurgery, Moscow, Russia

Recent and planned developments in pharmaceutical policies 2016 Special topic: Out-of pocket payments

DEVELOPMENTS

CHANGES IN PRICING

The List of Vital and Essential Medicines (LVEM)
(about 600 INN):

We still have fixed pricing process for medicines from
LVEM:

	0.71 Euro and less	0.71-7.1 Euro	More than 7.1 Euro
Wholesale margins, %	20	15	10
Retails margins, %	32	28	15

From the 1st of January 2017 we are expecting the
cancellation the rules according medicines from LVEM
with prices lower than 0.71 Euro

CHANGES IN REIMBURSEMENT

There is new List of Vital and Essential
Medicines in Russia since the 1st of March
2016. There are 43 new INN in it:
antithrombotic, antianemic, antiviral,
antineoplastic medicines, medicines for nervous
system and psychiatric (psychotropic and
antidepressants)

Minimal List of medicines presented in every
pharmacy and List of medicines for
appointment of medical commission were also
reviewed and approved from 1st of March 2016

OTHER CHANGES

- The introduction of the strict governmental control for pricing according medicines from the List of Vital and Essential medicines
- Preferences for Companies with localized manufacturing process in Russian Federation

SPECIAL TOPIC

OUT-OF POCKET PAYMENTS

100 % reim. - for medicines from positive list for Federal (“7 the most expensive nosology”, tuberculosis, HIV, vaccines according to National immunization schedule) or Regional State Programs (oncology, 24 rare diseases, rheumatoid arthritis)

100 % reim. - for some vulnerable groups (disabled children till 18 years, adults with disability of I group).

Co-payment: **50%** for some vulnerable groups (unemployed adults with disability of II and III groups);
13% - for all working citizens or their children or other direct relatives from the positive list

The out-pocket payment is about 3.2% from GDP. The volume of in-pocket segment is also about 3.2-3.4% GDP

In-pocket sector provides medicines according to Federal and Regional programs for patients with rare diseases, oncology, diabetes II type, after organ or tissue transplantation and some others. Also it provides full coverage for treatment in the hospital